Compounding: Groups Tell FDA To Drop “Traditional” and “Non-Traditional” Categories
Executive Summary
Stakeholders say it would create more confusion in the pharmacy and regulatory community; they also spar over whether volume, other criteria should be imposed to distinguish compounding types.
You may also be interested in...
Drug Shortages: FDA Says Market Must Reward Production Quality
FDA officials state in journal article that manufacturers are not incentivized to ensure quality and base competition entirely on price.
FDA Shortage Notification Mandate May Not Extend To Biologics
The agency has the option to issue regulations requiring biologics manufacturers to notify FDA of emerging production problems, but so far it’s only “something that we’re thinking about.”
Biden COVID-19 Plan Would Grow Domestic Manufacturing Base
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: